Mammalian telomerase
AssigneeGeron Corporation
InventorsBryant Villeponteau, Junli Feng, Walter Funk, William H. Andrews
Life of this patent
Estimating the term…
Abstract
Nucleic acids comprising the RNA component of a mammalian telomerase are useful as pharmaceutical, therapeutic, and diagnostic reagents.
Claims18
A method for inhibiting telomerase activity in human cells, comprising contacting the human cells in vivo with an exogenous oligonucleotide in an amount sufficient to inhibit telomerase activity, the oligonucleotide comprising at least 10 consecutive nucleotides exactly complementary to a human telomerase RNA component sequence,
- wherein the human telomerase RNA component comprises a sequence located in an ˜2.5 kb HindIII-SacI insert of plasmid pGRN33 (ATCC 75926),
- wherein the oligonucleotide does not consist of a plurality of 5′-TTAGGG-3′ telomeric repeat units, and
- wherein the oligonucleotide inhibits telomerase activity.
A method for inhibiting telomerase activity in human cells, comprising contacting the human cells in vivo with an exogenous oligonucleotide in an amount sufficient to inhibit telomerase activity, the oligonucleotide comprising more than 12 consecutive nucleotides exactly complementary to a human telomerase RNA component sequence,
- wherein the human telomerase RNA component comprises a sequence located in an ˜2.5 kb HindIII-SacI insert of plasmid pGRNT33 (ATCC 75926), and
- wherein the oligonucleotide inhibits telomerase activity.
A method for inhibiting telomerase activity in human cells, comprising contacting the human cells in vivo with an exogenous oligonucleotide in an amount sufficient to inhibit telomerase activity, the oligonucleotide comprising at least 10 consecutive nucleotides exactly complementary to SEQ ID NO:1,
- wherein the oligonucleotide does not consist of a plurality cif 5′-TTAGGG-3′ telomeric repeat units, and
- wherein the oligonucleotide inhibits telomerase activity.
A method for inhibiting telomerase activity in human cells, comprising contacting the human cells in vivo with an exogenous oligonucleotide in an amount sufficient to inhibit telomerase activity, the oligonucleotide comprising more than 12 consecutive nucleotides exactly complementary to SEQ ID NO:1,
- wherein the oligonucleotide inhibits telomerase activity.
Dependencies are inferred from the claim text.